Cargando…
Recurrent Intrahepatic Cholangiocarcinoma – Review
Intrahepatic cholangiocarcinoma (ICC) is the second-most common primary liver malignancy after hepatocellular carcinoma. While surgical resection with negative margin is the only curative treatment, ICC has very high rate of recurrence, up to 60-70% after curative resection. We reviewed the current...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8567135/ https://www.ncbi.nlm.nih.gov/pubmed/34746017 http://dx.doi.org/10.3389/fonc.2021.776863 |
_version_ | 1784594170751483904 |
---|---|
author | Bekki, Yuki Von Ahrens, Dagny Takahashi, Hideo Schwartz, Myron Gunasekaran, Ganesh |
author_facet | Bekki, Yuki Von Ahrens, Dagny Takahashi, Hideo Schwartz, Myron Gunasekaran, Ganesh |
author_sort | Bekki, Yuki |
collection | PubMed |
description | Intrahepatic cholangiocarcinoma (ICC) is the second-most common primary liver malignancy after hepatocellular carcinoma. While surgical resection with negative margin is the only curative treatment, ICC has very high rate of recurrence, up to 60-70% after curative resection. We reviewed the current data available on risk factors for ICC recurrence, recurrence pattern (location and timing), treatment options, and future directions. The risk factors for recurrence include elevated preoperative CA19-9, presence of liver cirrhosis, nodal metastasis, positive margins, and vascular invasion. Understanding different recurrence patterns, timing course, and risk factors for early recurrence is important to tailor postoperative surveillance and select treatment strategies including systemic or locoregional therapy. Re-resection can be considered for a selected patient population at experienced centers, and can yield long-term survival. ICC remains a dismal disease given the high likelihood of recurrence. Advances in our understanding of the genomic landscape of ICC are beginning to identify targetable alterations in ICC in subsets of patients that allow for personalized treatment. |
format | Online Article Text |
id | pubmed-8567135 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-85671352021-11-05 Recurrent Intrahepatic Cholangiocarcinoma – Review Bekki, Yuki Von Ahrens, Dagny Takahashi, Hideo Schwartz, Myron Gunasekaran, Ganesh Front Oncol Oncology Intrahepatic cholangiocarcinoma (ICC) is the second-most common primary liver malignancy after hepatocellular carcinoma. While surgical resection with negative margin is the only curative treatment, ICC has very high rate of recurrence, up to 60-70% after curative resection. We reviewed the current data available on risk factors for ICC recurrence, recurrence pattern (location and timing), treatment options, and future directions. The risk factors for recurrence include elevated preoperative CA19-9, presence of liver cirrhosis, nodal metastasis, positive margins, and vascular invasion. Understanding different recurrence patterns, timing course, and risk factors for early recurrence is important to tailor postoperative surveillance and select treatment strategies including systemic or locoregional therapy. Re-resection can be considered for a selected patient population at experienced centers, and can yield long-term survival. ICC remains a dismal disease given the high likelihood of recurrence. Advances in our understanding of the genomic landscape of ICC are beginning to identify targetable alterations in ICC in subsets of patients that allow for personalized treatment. Frontiers Media S.A. 2021-10-21 /pmc/articles/PMC8567135/ /pubmed/34746017 http://dx.doi.org/10.3389/fonc.2021.776863 Text en Copyright © 2021 Bekki, Von Ahrens, Takahashi, Schwartz and Gunasekaran https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Bekki, Yuki Von Ahrens, Dagny Takahashi, Hideo Schwartz, Myron Gunasekaran, Ganesh Recurrent Intrahepatic Cholangiocarcinoma – Review |
title | Recurrent Intrahepatic Cholangiocarcinoma – Review |
title_full | Recurrent Intrahepatic Cholangiocarcinoma – Review |
title_fullStr | Recurrent Intrahepatic Cholangiocarcinoma – Review |
title_full_unstemmed | Recurrent Intrahepatic Cholangiocarcinoma – Review |
title_short | Recurrent Intrahepatic Cholangiocarcinoma – Review |
title_sort | recurrent intrahepatic cholangiocarcinoma – review |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8567135/ https://www.ncbi.nlm.nih.gov/pubmed/34746017 http://dx.doi.org/10.3389/fonc.2021.776863 |
work_keys_str_mv | AT bekkiyuki recurrentintrahepaticcholangiocarcinomareview AT vonahrensdagny recurrentintrahepaticcholangiocarcinomareview AT takahashihideo recurrentintrahepaticcholangiocarcinomareview AT schwartzmyron recurrentintrahepaticcholangiocarcinomareview AT gunasekaranganesh recurrentintrahepaticcholangiocarcinomareview |